Sign up
Pharma Capital

NetScientific to delist from AIM and become a private company following strategic review

The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio companies
Scientist
NetScientific invests in development-stage medical and healthcare businesses

NetScientific PLC (LON:NSCI) has said it is looking to delist from AIM and re-register as a private company following a strategic review into its operations.

The firm, which invests in development-stage medical and healthcare businesses, said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” to enable as much of its remaining cash as possible be allocated to its portfolio companies.

READ: NetScientific says continuing to assess all remaining strategic options after closing formal sale process​

The company also said it had failed to generate any interest in a possible sale or to elicit and offers for the firms in its portfolio, adding that its cash resources as of 31 December were £3.3mln.

Shares were down 44% at 4.5p.​​

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.